<html><body>
<h1>Case: TwoDrugs_GlipX_ADRglip_MFb_eGFR40old_sub_cantIncrB_407</h1>
65.0 year old White Male
<p><b>Numeric Data Values:</b></p>
<table>
<tr><td width="200">Diabetes Testing</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;<b>HbA1C</b></td><td width="200">10.0</td><td width="200">2013-6-11</td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Glycosylated_Hemoglobin</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;PPG</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Blood Chemistry</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;Chem7</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sodium</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Potassium</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chloride</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Bicarbonate</b></td><td width="200">25</td><td width="200">2013-6-11</td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BUN</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Creatinine</b></td><td width="200">1.50</td><td width="200">2013-6-11</td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>eGFR</b></td><td width="200">40.0</td><td width="200">2011-6-11</td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Glucose</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;Lipid Panel</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total_Cholesterol</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HDL_Cholesterol</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LDL_Cholesterol</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Calculated_LDL</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Direct_Measure_LDL</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Triglycerides</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Liver panel</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Albumin</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alkaline_phosphatase</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>AST</b></td><td width="200">40.0</td><td width="200">2013-6-11</td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>ALT</b></td><td width="200">40.0</td><td width="200">2013-6-11</td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total_Bilirubin</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Chemistry panel misc</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Calcium</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Creatine_Phosphokinase_CPK_or_CK</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phosphorus</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Uric_Acid</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B 12</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Urine chemistry</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Creatinine_Clearance</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Microalbumin</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">CHF tests</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;BNP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;NT_proBNP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Hematology</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;AGN</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;CBC</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;HCT</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;HGB</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;PLT</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;WBC</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Microbiology_Tests</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Hepatitis_B_Surface_Antigen</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Hepatitis_C_Status</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;HIV_Test</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Pulmonary_Function_Studies</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;DCL</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;DLCO</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;FEV1</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;FVC</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">respiratory gas exchange</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">target_HBA1c</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Urinalysis</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Urine_Alb/creat_Ratio_24h</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Urine_ALB/CREAT_RATIO_spot</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineAlbumin_24H</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineAlbumin_SPOT</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineProtein_12h</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineProtein_24h</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineProtein_Qualitative</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineProtein_Spot</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Vital_Signs</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;<b>Diastolic_BP</b></td><td width="200">79</td><td width="200">2013-6-11</td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment_Diastolic_BP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DB_Diastolic_BP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;<b>Systolic_BP</b></td><td width="200">120</td><td width="200">2013-6-11</td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment_Systolic_BP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DB_Systolic_BP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;BMI</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Height</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;High_Cardiovascular_Risk</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Metabolic_Syndrome</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Pulse</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Weight</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200"><p>Others:</td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;<b>Age</b></td><td width="200">65</td><td width="200">1970-1-1</td></tr>
</table>
<p><b>Medications:</b> GLIPIZIDE(20.0[2013-02-27,  ]) METFORMIN(2000.0[2013-02-27,  ]) lisinopril(20.0[2013-02-27,  ]{91.0, 2013-02-27}) 
<p><b>Qualitative Data:</b> </p><table>
<tr><td width="200">Diabetes Type 2</td><td width="200"></td><td width="200">2013-2-27</td></tr>
<tr><td width="200">Race</td><td width="200">White</td><td width="200"></td></tr>
<tr><td width="200">Session Date</td><td width="200">2013-07-3</td><td width="200">2013-7-3</td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
</table><p>
<p><b>Allergies and Adverse Reactions:</b> <ul>
<li>Substance: GLIPIZIDE Reaction: Anaphylaxis
 </ul>
<h2 align="center">ATHENA DM:  Glycemic Control Dashboard</h2>
<p><b> KB loaded from /Users/tu/Documents/Dropbox/VA/ATHENA/athenakbs/ATHENA_DM_GlycemicControl_Dashboard.pprj</b>(last modified: 05/31/2018)</p><p></p>
<b>Patient classification:</b> <ul>
<li>ATHENA DM:  Glycemic Control Dashboard: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(65.0:01/01/1970) && NOT (Pres of DM-1 and Abs of DM-2) && Age(65.0:01/01/1970))</i>]
</ul>
<b>Scenario choice:</b> Scenario on One or Two encoded drugs not insulin
<p>
<b>Goal:</b> HbA1c <= 9%(Presence of HbA1c)
<p><b>Reached goal?</b> failed(HbA1c(10.0:06/11/2013))
<p><b>Action Choices</b>
<ul>
<li><b>dAll CDS scenarios No ACE/ARB</b><br>
<ul>
<li><b>Metformin checks <font color=FF0000>preferred</font></b>(rule in criterion<i> Pres biguanide and not biguanide contraindicated</i> evaluate to <b> true</b> because <i>not biguanide contraindicated</i>)])
<ul>
<li>[General_Info; fine-grain-priority=100] Check B12 levels every 2 years as pt has Rx for metformin.</li><li>[General_Info; fine-grain-priority=100] Rx for metformin.  Check GFR annually.</li></ul>
<li><b>Msg start Insulin <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[General_Info; fine-grain-priority=100] If pt has severe hyperglycemia or excessive symptoms, consider starting insulin.</li></ul>
<li><b>Set target HbA1c 2017 <font color=FF0000>preferred</font></b>(rule in criterion<i> Absence Target HBA1c</i> evaluate to <b> true</b> )])
<ul>
<li>[General_Info; fine-grain-priority=300] Refer to  <a href="https://vaww.fre.cdw.va.gov/sites/D05_VISN21/Documents/CDS/VADoD_DM_CPG_2017.pdf#page=35"> Table 2 from VA 2017 DM Guidelines </a> to determine HbA1c target.</li></ul>
<li><b>Shared Decision Making Action <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[General_Info; fine-grain-priority=300] Strongly recommend shared decision making process, where pt, family and provider agree to plan of care and treatment. Info available <a href="https://vaww.fre.cdw.va.gov/sites/D05_VISN21/Documents/CDS/VADoD_DM_CPG_2017.pdf#page=23"> here</a>.</li></ul>
<li><b>TLC <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[General_Info; fine-grain-priority=300] Lifestyle changes to control DM.  Info available <a href="https://vaww.fre.cdw.va.gov/sites/D05_VISN21/Documents/CDS/VADoD_DM_CPG_2017.pdf#page=37"> here</a>.</li></ul>
</ul>
<li><b>dTwo drug choices II</b><br>
<ul>
<li><b>Make rec's <font color=FF0000>preferred</font></b>(strict rule-in condition<i> not at goal and not bad TZD and gemfibrozil</i> evaluate to <b> true</b> because <i>HbA1c(10.0:06/11/2013) && NOT (Pres gemfibrozil and TZD and not TZD contra)</i>)])
</ul>
<li><b>Can Intensify or Sub</b><br>
<ul>
<li><b>dIntensify II <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<li><b>dSubstitute <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of contraindication and no bad drug partner DM</i> evaluate to <b> true</b> )])
<ul>
<li>Evaluate_Substitution_Activity dEvaluate substitution first line agent  fine-grain priority: 100</li></ul>
</ul>
<li><b>dIntensify choices II</b><br>
<ul>
<li><b>dIncrease dose <font color=FF0000>preferred</font></b>(strict rule-in condition<i> there exists non-contraindicated meds not at max level according to DM guideline</i> evaluate to <b> true</b> )])
<ul>
<li>Evaluate_Increase_Activity_Intensity consider increasing dose of drugs  fine-grain priority: 300</li></ul>
</ul>
<li><b>No 1st or 2nd ine drug rec sub</b><br>
<ul>
<li><b>Follow up msg sub <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of oral hypoglycemic agent rec_add</i> evaluate to <b> true</b> )])
<ul>
<li>[Follow_Up; fine-grain-priority=100] Follow up in 3 months</li></ul>
</ul>
<li><b>dNo Incr dose choice</b><br>
<ul>
<li><b>Msg follow up 3 months incr dose <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Pres non-insulin agent rec incr or block incr</i> evaluate to <b> true</b> )])
<ul>
<li>[Follow_Up; fine-grain-priority=100] Follow up in 3 months</li></ul>
</ul>
</ul>
<b>Considerations for substituting drug: </b><ul>
<li> Substitution: replace 
<ul>
<li>GLIPIZIDE(GLIPIZIDE)
<ul>
<li>Is second-line drug for:  Diabetes Type 2(DM-Type2) 
<li>Contraindications:  ADR anaphylaxis to glipizide([Adverse_Reaction(Anaphylaxis)]) 
<li>Adverse reaction: Glipizide(Anaphylaxis)
<li>preference: preferred
<li>fine-grained priority: 100
</ul>
 with <li>Saxagliptin
<ul>
<li>Is second-line drug for:  Diabetes Type 2(DM-Type2) 
<li>Relative contraindications:  eGFR<45 most recent any time frame([eGFR(40.0:06/11/2011)]) 
<li>Recommendation basis: is second-line drug for
<li>Do not add controllable conditions:  Absence of eGFR in past 30 days() 
<li>preference: blocked
<li>fine-grained priority: 100
<ul>
<li>[do_not_add_controllable_condition; fine-grain-priority=100] Would add saxagliptin, but old GFR: 40.0 (2011/6/11).</li><li>Order test or procedure:eGFRfine-grain priority: 0</li><li>[General_Info; fine-grain-priority=100] Adjust saxagliptin for renal impairment or with CYP3A4/5 inhibitor.</li></ul>
</ul>
<li>Thiazolidinediones
<ul>
<li>specific drug(s): Pioglitazone</li>
<li>Is second-line drug for:  Diabetes Type 2(DM-Type2) 
<li>Recommendation basis: is second-line drug for
<li>preference: preferred
<li>fine-grained priority: 100
<ul>
<li>[General_Info; fine-grain-priority=100] Check liver tests q3 months for 1 year.</li><li>[General_Info; fine-grain-priority=100] Hold metformin prior to and 48 hrs after IV contrast studies.</li><li>[General_Info; fine-grain-priority=100] Caution in presence CYP2C8 inhibitor (e.g. gemfibrozil) or CYP2C8 inducer (e.g. rifampin).</li></ul>
</ul>
</ul>

</ul>
<b>If changing attribute, consider: </b><ul>
<li>Metformin(change daily_dose: up<ul><li>blocked
<li><font color=FF0000>Is first-line drug for:  Diabetes Type 2(DM-Type2) </font>
<li>do not intensify conditions:  Absence of eGFR in past year() 
<li>do not decrease dose conditions:  Absence of eGFR in past year() 
 <li> fine-grained priority: 300</ul>)
<ul>
<li>Order test or procedure:eGFRfine-grain priority: 0</li><li>[do_not_intensify_controllable_condition; fine-grain-priority=100] Cannot recommend increasing metformin when GFR &lt; 45 and old: 40.0 (2011/6/11)</li></ul>

</ul>
null<h2>Session time: 2013-07-3</h2>
<h2>GuidelineID: ATHENA DM:  Glycemic Control Dashboard</h2>
<h4>System Conclusions</h4>
<pre>
Conclusion: ATHENA DM:  Glycemic Control Dashboard Value: true
Case is eligible
</pre>
<p>
<b>Guideline Goal: HbA1c <= 9%</b>
(Presence of HbA1c)<p><b>Reached goal?</b> failed(HbA1c(10.0:06/11/2013))
<h4>Recommended Actions</h4>
<pre>
 <b>Message: On Metformin check serum B12 level</b>
 Message Type: General_Info
 Fine-grain priority: 100
 Message: Check B12 levels every 2 years as pt has Rx for metformin.
 <b>Message: On metformin check GFR</b>
 Message Type: General_Info
 Fine-grain priority: 100
 Message: Rx for metformin.  Check GFR annually.
 <b>Message: Msg Start insulin</b>
 Message Type: General_Info
 Fine-grain priority: 100
 Message: If pt has severe hyperglycemia or excessive symptoms, consider starting insulin.
 <b>Message: Set target HbA1c 2017</b>
 Message Type: General_Info
 Fine-grain priority: 300
 Message: Refer to  <a href="https://vaww.fre.cdw.va.gov/sites/D05_VISN21/Documents/CDS/VADoD_DM_CPG_2017.pdf#page=35"> Table 2 from VA 2017 DM Guidelines </a> to determine HbA1c target.
 <b>Message: Shared Decision Making Msg</b>
 Message Type: General_Info
 Fine-grain priority: 300
 Message: Strongly recommend shared decision making process, where pt, family and provider agree to plan of care and treatment. Info available <a href="https://vaww.fre.cdw.va.gov/sites/D05_VISN21/Documents/CDS/VADoD_DM_CPG_2017.pdf#page=23"> here</a>.
 <b>Message: TLC</b>
 Message Type: General_Info
 Fine-grain priority: 300
 Message: Lifestyle changes to control DM.  Info available <a href="https://vaww.fre.cdw.va.gov/sites/D05_VISN21/Documents/CDS/VADoD_DM_CPG_2017.pdf#page=37"> here</a>.
 <b>Evaluate_Substitution_Activity: dEvaluate substitution first line agent</b>
 <b>Evaluate_Increase_Activity_Intensity: consider increasing dose of drugs</b>
 <b>Message: Follow up in 3 months</b>
 Message Type: Follow_Up
 Fine-grain priority: 100
 Message: Follow up in 3 months
</pre>
<h4>Therapeutic Choices</h4>
<pre>

<b>discontinue: </b>GLIPIZIDE
<b>Fine-grain priority: </b>100
<b>strong_contraindication</b>: ADR anaphylaxis to glipizide
<b>is_second_line_drug_for</b>: Diabetes Type 2
<b>Adverse Reaction:</b>Glipizide(Anaphylaxis)
<b>add: </b>Saxagliptin
<b>Preference: </b>blocked
<b>Fine-grain priority: </b>100
<b>relative_contraindication</b>: eGFR<45 most recent any time frame
<b>do_not_add_controllable_condition</b>: Absence of eGFR in past 30 days
<b>is_second_line_drug_for</b>: Diabetes Type 2
<b>Collateral Actions: </b>
      <b>Message: Param msg sax missing GFR past month</b>
      Message Type: do_not_add_controllable_condition
      Fine-grain priority: 100
      Message: Would add saxagliptin, but old GFR: 40.0 (2011/6/11).
      <b>Order_TestProcedure: Order eGFR - missing past month</b>
      Test or Procedure: eGFR
      Fine-grain priority: 0
      <b>Message: Sax dose adjustment</b>
      Message Type: General_Info
      Fine-grain priority: 100
      Message: Adjust saxagliptin for renal impairment or with CYP3A4/5 inhibitor.

<b>discontinue: </b>GLIPIZIDE
<b>Fine-grain priority: </b>100
<b>strong_contraindication</b>: ADR anaphylaxis to glipizide
<b>is_second_line_drug_for</b>: Diabetes Type 2
<b>Adverse Reaction:</b>Glipizide(Anaphylaxis)
<b>add: </b>Thiazolidinediones(Pioglitazone)
<b>Preference: </b>preferred
<b>Fine-grain priority: </b>100
<b>is_second_line_drug_for</b>: Diabetes Type 2
<b>Collateral Actions: </b>
      <b>Message: Warning about liver enzymes check in 1st year</b>
      Message Type: General_Info
      Fine-grain priority: 100
      Message: Check liver tests q3 months for 1 year.
      <b>Message: Warning for intravascular iodinated radiocontrast studies</b>
      Message Type: General_Info
      Fine-grain priority: 100
      Message: Hold metformin prior to and 48 hrs after IV contrast studies.
      <b>Message: TZD CYP2C8 warning</b>
      Message Type: General_Info
      Fine-grain priority: 100
      Message: Caution in presence CYP2C8 inhibitor (e.g. gemfibrozil) or CYP2C8 inducer (e.g. rifampin).

<b>Drug Action Type:</b> increase_dose
<b>Preference: </b>blocked
<b>Fine-grain Priority: </b>300
Specific Drug: Metformin
<b>do_not_intensify_condition</b>: Absence of eGFR in past year
<b>is_first_line_drug_for</b>: Diabetes Type 2
<b>Collateral Actions: </b>
      <b>Order_TestProcedure: Order eGFR - missing past year</b>
      Test or Procedure: eGFR
      Fine-grain priority: 0
      <b>Message: Old eGFR LOW for incr MF</b>
      Message Type: do_not_intensify_controllable_condition
      Fine-grain priority: 100
      Message: Cannot recommend increasing metformin when GFR &lt; 45 and old: 40.0 (2011/6/11)
</pre>
<br><br></body></html>
